Browse Studies — Arctuva

A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a North American Miltenyi Biomedicine-Sponsored Clinical Study

This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

Non Hodgkin LymphomaRefractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell Lymphoma+3 more

Estimated

~$10 – $1,050

Miltenyi Biomedicine GmbHNCT06116110

Phase 1

A Phase Ib, Dose-Escalation Study of Augmented Lymphodepletion and CAR T-cell Priming With Low-dose Total Body Irradiation in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphomas and Multiple Myeloma Receiving Treatment With Commercial CD19 or BCMA-directed CAR T-cell Therapies

This is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD-TBI) in patients with previously treat…

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed or Refractory Multiple Myeloma (MM)

Estimated

~$10 – $6,250

Weill Medical College of Cornell UniversityNCT07725406

Phase 2

A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) i…

Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell LymphomaHigh Grade B-cell Lymphoma (HGBCL)+6 more

Estimated

~$10 – $8,750

Miltenyi Biomedicine GmbHNCT04792489